The effect of antihypertensive drugs on arterial stiffness and central hemodynamics: Not all fingers are made the same

Open Hypertension Journal

Volumn 5, Issue SPEC.ISSUE, 2013, Pages 75-81

  Doumas, M ^a,b   Gkaliagkousi, E ^a   Katsiki, N ^a   Reklou, A ^a   Lazaridis, A ^a   Karagiannis, A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Antihypertensive drugs; Aortic blood pressure; Arterial stiffness; Augmentation index; Beta blockers; Central hemodynamics; Pulse wave velocity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; LABETALOL; NEBIVOLOL; VALSARTAN;

ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; END STAGE RENAL DISEASE; HEMODYNAMICS; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM;

EID: 84896816349     PISSN: None     EISSN: 18765262     Source Type: Journal    
DOI: 10.2174/1876526201305010075     Document Type: Article

References (83)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-357.
2. Shokawa T, Imazu M, Yamamoto H, et al. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259-64.
3. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-70.
4. Anderson SG, Sanders TA, Cruickshank JK. Plasma fatty acid composition as a predictor of arterial stiffness and mortality. Hypertension 2009; 53: 839-45.
5. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events. The Framingham Heart Study. Circulation 2010; 121: 505-11.
6. Wang KL, Cheng HM, Sung SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension 2010; 55: 799-805.
7. Meaume S, Benetos A, Henry OF, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects 70 years of age. Arterioscler Thromb Vasc Biol 2001; 21: 2046-50.
8. Mattace-Raso FU, Vander Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-63.
9. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005; 111: 3384-90.
10. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005; 45: 426-31.
11. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-90.
12. Mansour AS, Yannoutsos A, Majahalme N, et al. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens 2013; 31: 1584-92.
13. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-41.
14. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39:10-5.
15. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34: 1203-6.
16. Terai M, Ohishi M, Ito N, et al. Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) Study. Hypertens Res 2008; 31: 1135-45.
17. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 21217-4.
18. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
19. Zoungas S, Cameron JD, Kerr PG, et al. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis 2007; 50: 622-30.
20. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005; 45: 592-6.
21. Karras A, Haymann JP, Bozec E, et al. Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease. Hypertension 2012; 60: 1451-7.
22. Gasecki D, Rojek A, Kwarciany M, et al. Aortic stiffness predicts functional outcome in patients after ischemic stroke. Stroke 2012; 43: 543-4.
23. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. J Am Coll Cardiol 2010; 55: 1318-27.
24. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-5.
25. Seherstedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91.
26. Seherstedt T, Jeppesen J, Hansen TW, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham, and ESH/ESC risk charts. J Hypertens 2012; 30: 1928-36.
27. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-5.
28. Mattace-Raso FU, Vander Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-63.
29. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events. The Framingham Heart Study. Circulation 2010; 121: 505-11.
30. Pini R, Cavallini MC, Palmieri V, et al. Central but not branchial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008; 51: 2432-9.
31. Roman MJ, Devereux RB, Kijer JR, et al. Central blood pressure more strongly relates to vascular disease and outcome than does branchial pressure: the Strong Heart Study. Hypertension 2007; 50: 197-203.
32. Dart AM, Gatzka CD, Kingwell BA, et al. Branchial blood pressure but not carotid arterial wave forms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785-90.
33. London GM, Blacher J, Pannier B, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-8.
34. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-8.
35. Covic A, Mardare N, Gusbeth-Tatomir P, et al. Arterial wave reflections and mortality in hemodialysis patients-only relevant in elderly, cardiovascular compromised? Nephrol Dial Transplant 2006; 21: 2859-66.
36. Lu TM, Hsu NW, Chen YH, et al. Pulsatility of ascending aorta and restenosis after coronary angioplasty in patients >60 years of age with stable angina pectoris. Am J Cardiol 2001; 88: 964-8.
37. Ueda H, Hayashi T, Tsumura K, et al. The timing of the reflected wave in the ascending aortic pressure predicts restenosis after coronary stent placement. Hypertens Res 2004; 27: 535-40.
38. Chirinos JA, Zambrano JP, Chakko S, et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45: 980-5.
39. Weber T, Auer J, O'Rourke MF, et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur Heart J 2005; 26: 2657-63.
40. Jankowski P, Kawecka-Jaczcz K, Czarnecka D, et al. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008; 51: 848-55.
41. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central hemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-71.
42. Davies JE, Malaweera A, Lacy PS, et al. Wave pressure is higher in atenolol treated individuals and independently predicts cardiovascular events in the CAFÉ substudy of ASCOT. J Am Coll Cardiol 2011; S173.
43. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987-92.
44. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
45. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure lowering drugs on central aortic pressur and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-25.
46. Yu WC, Lin YP, Lin IF, et al. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 2006; 47: 478-84.
47. Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007; 298: 1539-47.
48. Rahman S, Ismail AA, Ismail SB, et al. Effect of rosiglitazone/ ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomized, double-blind, placebo-controlled study. Eur J Clin Pharmacol 2007; 63: 73-741.
49. Mitchell GF, Dunlap ME, Warnica W, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic study. Hypertension 2007; 49: 1271-7.
50. Ahimastos AA, Dart AM, Lawler A, et al. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens 2008; 26: 1037-42.
51. Benetos A, Gautier S, Lafleche A, et al. Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000; 37: 8-15.
52. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-4.
53. Pannier BM, Lafleche AB, Girerd XJ, et al. Arterial stiffness and wave reflections following acute calcium blockade in essential hypertension. Am J Hypertens 1994; 7: 168-76.
54. Topouchian J, Brisac AM, Pannier B, et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study. J Hum Hypertens 1998; 12: 181-7.
55. Asmar RG, Benetos A, Darne BM, et al. Converting enzyme inhibition; dissociation between antihypertensive and arterial effecs. J Hum Hypertens 1992; 6: 381-5.
56. Benetos A, Lafleche A, Asmar R, et al. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens 1996; 10: 77-82.
57. Asmar RG, Benetos A, Chaouche-Teyara K, et al. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse wave velocity in essential hypertension. Am J Cardiol 1993; 72: 794-8.
58. Lafleche A, Gautier S, Topouchian J, et al. Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension. Clin Pharmacol Ther 1998; 64; 96-105.
59. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-5.
60. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439-44.
61. Rehman A, Ismail SB, Naing L, et al. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007; 20:184-9.
62. Ali K, Rajkumar C, Fantin F, et al. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risc Manage 2009; 5: 587-92.
63. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE-inhibition and calcium channel blockade. Circulation 1994; 90: 2786-96.
64. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54: 409-13.
65. Pannier BM, Guerin AP, Marchais SJ, et al. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001; 28: 1074-7.
66. Breithaupt-Grogler K, Leschinger M, Belz GG, et al. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther 1996; 10: 49-57.
67. Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press 2011; 20: 104-10.
68. Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces largeartery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194-9.
69. Deary AJ, Schumann AL, Murfet H, et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci 2002; 103: 493-9.
70. Dart AM, Reid CM, McGrath B. Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. Am J Hypertens 2001; 14; 804-10.
71. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002; 15: 24-30.
72. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFÉ (Conduit Artery Function Evaluation) study: CAFÉ-Heart Rate. J Am Coll Cardiol 2009; 54: 705-13.
73. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a metaanalysis and meta-regression of randomized controlled trials. Atherosclerosis 2012; 221: 18-33.
74. Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19: 214-9.
75. Schneider MP, Delles C, Kingbeil AU, et al. Effect of angiotensin receptor blockade on central hemodynamics in essential hypertension: results of a randomized trial. J Renin Angiotensin Aldosterone Syst 2008; 9: 49-56.
76. Boutouyrie P, Achouba A, Trunet P, et al. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010; 55: 1314-22.
77. Polonia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with b-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit 2010; 15: 235-9.
78. Merchant N, Searles CD, Pandian A, et al. Nebivolol in high-risk, obese African-Americans with Stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. J Clin Hypertens 2009; 11: 720-5.
79. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21: 663-7.
80. Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351-6.
81. Kelly R, daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989; 14: 14-21.
82. Shah NK, Smith SM, Nichols WW, et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL study). J Clin Hypertens 2011; 13: 917-24.
83. Park S, Rhee MY, Lee SY, et al. A prospective, randomized, openlabel, active-controlled, clinical trial to assess central hemodynamic effects of bisoprolol and atenolol in hypertensive patients. J Hypertens 2013; 31: 813-9.